Diagnostic Value of Prostatic Acid Phosphatase (Pap) and Prostate-Specific Antigen (Psa) in Patients with Prostatic Cancer

1992 ◽  
Vol 59 (1) ◽  
pp. 101-103
Author(s):  
T. Zambolin ◽  
L. Tralce ◽  
A. Cozzoli ◽  
E. Frego ◽  
C. Simeone ◽  
...  
Keyword(s):  
Acid Phosphatase ◽  
Prostatic Carcinoma ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Diagnostic Value ◽  
High Risk Population ◽  
Specific Substrate ◽  
Clinical Value ◽  
Receiver Operating Characteristic Curves ◽  
Clinical Accuracy

Prostatic acid phosphatase (PAP) and specific prostatic antigen (PSA) in the serum of patients with prostatic carcinoma were determined and their clinical value compared. 128 patients were examined, 60 (46.9%) of whom had prostatic carcinoma (4 in stage T2, 27 in T3 and 29 in T4) and 68 with benign prostatic pathology. ROC (receiver operating characteristic) curves were plotted from resulting data and the underlying areas calculated to evaluate the clinical accuracy of the two markers. The area for PSA (0.90 +/-0.03) was significantly greater than that for PAP (0.71 +/-0.05), showing that PSA was better at detecting patients with or without prostatic carcinoma. Maximum clinical accuracy was 0.883 obtained with discriminating values of 0.8 U/L for PAP and 10 ug/L for PSA, confirming the superiority of PSA. However, PAP determination using thymolphthalein monophosphate as the specific substrate for the prostatic isoenzyme, showed greater clinical specificity (98.5%) so that association of the two markers made it possible to eliminate false positive results. In conclusion, results suggest the possibility of using PSA for diagnosing prostatic carcinoma in a selected high risk population. However, the simplicity of the method used for determining PAP and the greater clinical specificity of PAP and PSA combined, suggest determining both parameters for diagnostic purposes.

Prostatic Acid Phosphatase (PAP) Differentiated Ultracytochemically from Lysosomal Acid Phosphate in the Rat with a PAP/Specific Substrate, Phosphorylcholine

1975 ◽  
Vol 33 ◽  
pp. 450-451
Author(s):  
W. Allen Shannon ◽  
José A. Serrano ◽  
Hannah L. Wasserkrug ◽  
Anna A. Serrano ◽  
Arnold M. Seligman
Keyword(s):  
Acid Phosphatase ◽  
Phosphate Buffer ◽  
Prostatic Carcinoma ◽  
Prostatic Acid Phosphatase ◽  
Chemotherapeutic Agents ◽  
Specific Substrate ◽  
Acid Phosphate ◽  
Lysosomal Acid ◽  
Design And Synthesis ◽  
New Chemotherapeutic Agents

During the design and synthesis of new chemotherapeutic agents for prostatic carcinoma based on phosphorylated agents which might be enzyme-activated to cytotoxicity, phosphorylcholine, [(CH3)3+NCH2CH2OPO3Ca]Cl-, has been indicated to be a very specific substrate for prostatic acid phosphatase (PAP). This phenomenon has led to the development of specific histochemical and ultracytochemical methods for PAP using modifications of the Gomori lead method for acid phosphatase. Comparative histochemical results in prostate and kidney of the rat have been published earlier with phosphorylcholine (PC) and β-glycerophosphate (βGP). We now report the ultracytochemical results.Minced tissues were fixed in 3% glutaraldehyde-0.1 M phosphate buffered (pH 7.4) for 1.5 hr and rinsed overnight in several changes of 0.05 M phosphate buffer (pH 7.0) containing 7.5% sucrose. Tissues were incubated 30 min to 2 hr in Gomori acid phosphatase medium (2) containing 0.1 M substrate, either PC or βGP.

Diagnostic Utility of P504S/p63 Cocktail, Prostate-Specific Antigen, and Prostatic Acid Phosphatase in Verifying Prostatic Carcinoma Involvement in Seminal Vesicles: A Study of 57 Cases of Radical Prostatectomy Specimens of Pathologic Stage pT3b

2010 ◽  
Vol 134 (7) ◽  
pp. 983-988 ◽  
Author(s):  
Aaron M. Harvey ◽  
Beverly Grice ◽  
Candice Hamilton ◽  
Luan D. Truong ◽  
Jae Y. Ro ◽  
...  
Keyword(s):  
Acid Phosphatase ◽  
Radical Prostatectomy ◽  
Seminal Vesicle ◽  
Prostate Specific Antigen ◽  
Prostatic Carcinoma ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Growth Patterns ◽  
Nuclear Staining ◽  
Pathologic Stage

Abstract Context.—Seminal vesicle invasion by prostatic carcinoma is directly associated with tumor staging; verification is challenging when the tumor demonstrates cribriform or papillary growth patterns or there are back-to-back small-gland proliferations. P504S is overexpressed in prostatic carcinoma and high-grade prostatic intraepithelial neoplasia with cytoplasmic immunoreactivity. p63 has positive immunoreactivity in basal cell nuclei of benign prostatic glands. Many researchers use a combination of these antibodies and their different colors. Objective.—To evaluate the usefulness of a single-color P504S/p63 cocktail immunostain in verifying prostatic carcinoma within the seminal vesicle. Design.—Sections from 57 radical prostatectomy specimens of pathologic stage pT3b that contain seminal vesicle with prostatic carcinoma involvement were immunostained with primary antibodies against prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) and a cocktail of antibodies against P504S and p63. Results.—Prostatic carcinoma cells from all 57 cases were diffusely positive for P504S, PSA, and PAP with cytoplasmic staining and no p63 nuclear staining. Seminal vesicle epithelium from all 57 cases was negative for all 3 markers with distinct p63 nuclear staining of the basal cells. Benign prostatic tissue was positive for PSA and PAP, as well as for p63, but negative for P504S. Conclusions.—The P504S/p63 one-color cocktail is a practical and cost-effective stain to differentiate prostatic carcinoma that involves the seminal vesicle from seminal vesicle epithelium. It is superior to PSA or PAP when sections contain both seminal vesicle and benign glands because PSA and PAP cannot distinguish benign from malignant glands.

scholarly journals IMMUNOHISTOCHEMICAL STUDY OF PROSTATIC ACID PHOSPHATASE AND PROSTATIC SPECIFIC ANTIGEN IN PROSTATIC CARCINOMA

1987 ◽  
Vol 78 (11) ◽  
pp. 1992-1997
Author(s):  
Nobuo Moriyama ◽  
Jun Taniguchi ◽  
Makoto Hara ◽  
Keiko Fukutani ◽  
Hisashi Matsushima ◽  
...  
Keyword(s):  
Acid Phosphatase ◽  
Prostatic Carcinoma ◽  
Immunohistochemical Study ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Prostatic Specific Antigen

Tumour Markers in Prostatic Cancer: Prostatic Acid Phosphatase (PAP), Prostatic Specific Antigen (PSA) and Lipid Associated Sialic Acid (LASA)

1994 ◽  
Vol 61 (4) ◽  
pp. 277-280
Author(s):  
B. Garibaldi ◽  
N. Rizzello ◽  
S. Rocca Rossetti ◽  
M. Tasso ◽  
A. Tizzani ◽  
...  
Keyword(s):  
Acid Phosphatase ◽  
Sialic Acid ◽  
Prostatic Cancer ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Cellular Membrane ◽  
Tumour Marker ◽  
Tumour Markers ◽  
Clinical Value ◽  
Tumour Extension

Among tumour markers in clinical practice, interest has been aroused by the products of the cellular membrane, such as LASA (Lipid Associated Sialic Acid). The aim of our work was to assess the clinical value of LASA in patients affected by prostatic cancer at different stages and grades, and to compare the usefulness of LASA as a tumour marker over Prostate Acid Phosphatase (PAP) and Prostate Specific Antigen (PSA), which are well known markers of tumour extension in prostatic cancer. In this study we perfomed serum dosage of LASA, PAP and PSA in fifty-five patients with prostatic adenocarcinoma, 10 cases of stage A1/A2, 13 B1/B2, 6 C1/C2 and 26 D1/D2. This study shows that LASA may complement diagnostic and prognostic values of other existing tumour markers for prostate cancer.

Sign in / Sign up

Export Citation Format

Share Document